OncoMed Pharmaceuticals, Inc. (OMED) Presents Data From Demcizumab Phase 1b Clinical Study In Pancreatic Cancer At The 2014 Gastrointestinal Cancers Symposium
1/17/2014 9:08:58 AM
SAN FRANCISCO, Jan. 17, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, presented data today from its ongoing Phase 1b clinical trial of demcizumab (OMP-21M18; anti-DLL4) in first-line Stage IV pancreatic cancer patients at the 2014 Gastrointestinal Cancers Symposium being held in San Francisco, California. These are the first reported data from the Phase 1b study of demcizumab with gemcitabine to include the addition of Abaxane® (nab-paclitaxel). Demcizumab is part of OncoMed's collaboration with Celgene Corporation.
Help employers find you! Check out all the jobs and post your resume.
comments powered by